WinstonWınston
High Sierra Technologies logo

High Sierra Technologies

HSTI
Drug Manufacturers - Specialty & Generic · Healthcare
Price
$1.40
+0.00 (+0.00%)
Market Cap
$29.3M
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+1.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 20.4M (2021) → 20.7M (2025)

High Sierra Technologies is a small healthcare company focused on developing and commercializing specialty pharmaceutical and drug delivery products. It targets niche therapeutic areas where generic or branded medications can be reformulated or improved for better patient use. The company operates in the specialty and generic drug manufacturing industry, competing alongside much larger pharmaceutical firms.

The company generates revenue through product sales and, potentially, licensing or partnership agreements tied to its drug formulations. It appears to operate primarily in the United States, and given its very small market capitalization, it remains an early-stage or micro-cap business with limited commercial scale. The key risk here is straightforward: with gross and operating margins reported at zero, the company has not yet demonstrated a profitable business model, and its ability to fund ongoing operations and bring products to market depends heavily on raising additional capital or securing meaningful commercial partnerships.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

Revenue declining

EPS Growth

+89.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

Research and development spending

Insider Activity

78.6%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$972 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

High Sierra Technologies has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
N/A
Data not available
Operating Margin
N/A
Data not available
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-100.0%
Shrinking sales (-100.0% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial